MorphoSys AG has announced the signing of a protein engineering agreement with a large bio-pharmaceutical company. The non-exclusive license agreement covers the delivery of multiple Slonomics®-based DNA libraries.
The libraries will encode a broad range of protein classes, excluding antibodies, and will be used by its partner for drug discovery.
MorphoSys will receive committed annual funding for the delivery of libraries over the three-year lifetime of the agreement and stands to receive milestone and royalty payments on each product emerging from the collaboration.
"This fourth alliance around the Slonomics technology further illustrates the value of the platform," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
Dr. Moroney continued, "Slonomics is a powerful method for making libraries of all types, and this agreement exemplifies the commercial opportunity it creates for us beyond the antibody field."
The Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre-determined positions with unprecedented speed.
The technology provides a new and flexible approach to generating optimized proteins. MorphoSys acquired Slonomics through Sloning BioTechnology in October 2010.